SCHEMBL6480667

SCHEMBL6480667

C/C=C/C(=O)C(=O)Nc1ccc2c(c1)c(C)cn2C(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.36
MAPT P10636 9/20 0.35
POLB P06746 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
TP53 P04637 3/20 0.34
THRB P10828 2/20 0.34
GAA P10253 2/20 0.34
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 1/20 0.32
TYK2 P29597 1/20 0.32
IDH1 O75874 2/20 0.32
APAF1 O14727 1/20 0.32
USP2 O75604 1/20 0.32
MAPK1 P28482 1/20 0.32
UBE2N P61088 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491491 0.80 F2R (0.51) MAPTPOLBSMN1; SMN2GAAKMT2A
SCHEMBL6480497 0.80 UBE2M (0.46) MAPTPOLBSMN1; SMN2KMT2ATYK2
SCHEMBL6490737 0.78 NPSR1 (0.46) RAB9ASMN1; SMN2GAAKMT2AALDH1A1
SCHEMBL6481370 0.78 NPSR1 (0.49) SMN1; SMN2GAAALDH1A1TYK2USP2
SCHEMBL6490018 0.78 ALDH1A1 (0.47) MAPTPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL6481498 0.74 TSHR (0.44) MAPTNPC1KMT2AALDH1A1IDH1
SCHEMBL6186086 0.71 MAPT (0.39) MAPTSMN1; SMN2THRBKMT2AALDH1A1
SCHEMBL6229816 0.70 RORC (0.43) MAPTPOLBSMN1; SMN2GAAKMT2A
SCHEMBL6492205 0.67 MAPT (0.41) MAPTPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL6206223 0.67 F2R (0.53) MAPTNPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 CHRNA7 3442/4885MAPT 3587/4885POLB 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.